For the quarter ended March 2024, Gilead Sciences (GILD) reported revenue of $6.69 billion, up 5.3% over the same period last year. EPS came in at -$1.32, compared to $1.37 in the year-ago quarter.The reported revenue represents a surprise of +5.59% over the Zacks Consensus Estimate of $6.33 billion. With the consensus EPS estimate being -$1.49, the EPS surprise was +11.41%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street ...

Gilead Sciences (GILD) came out with a quarterly loss of $1.32 per share versus the Zacks Consensus Estimate of a loss of $1.49. This compares to earnings of $1.37 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 11.41%. A quarter ago, it was expected that this HIV and hepatitis C drugmaker would post earnings of $1.76 per share when it actually produced earnings of $1.72, delivering a surprise of -2.27%.Over the last four quar ...

GILEAD SCIENCES ANNOUNCES FIRST QUARTER 2024 FINANCIAL RESULTS Product Sales Excluding Veklury Increased 6% Year-Over-Year to $6.1 billion Biktarvy Sales Increased 10% Year-Over-Year to $2.9 billion Oncology Sales Increased 18% Year-Over-Year to $789 million Closed CymaBay Acquisition Resulting in $3.9 billion Acquired IPR&D Charge ($3.14 Diluted EPS Impact) Foster City, CA, April 25, 2024 - Gilead Sciences, Inc. (Nasdaq: GILD) announced today its first quarter 2024 results of operations. “Gilead delivered ...

Gilead Sciences Inc. (GILD) is set to report first-quarter 2024 results on Apr 25, after market close. In the last reported quarter, the company posted an earnings surprise of -2.27%.Factors to NoteGilead has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy and Descovy. However, revenues in the first quarter might have been impacted by a decline in HIV franchise sales. The first quarter is typically impacted by the reset of patient copays and deductibles. In addition, inventory build ...

In the latest trading session, Gilead Sciences (GILD) closed at $66.16, marking a -1.15% move from the previous day. The stock fell short of the S&P 500, which registered a loss of 0.22% for the day. Elsewhere, the Dow gained 0.06%, while the tech-heavy Nasdaq lost 0.52%.The HIV and hepatitis C drugmaker's stock has dropped by 9.53% in the past month, falling short of the Medical sector's loss of 6.22% and the S&P 500's loss of 1.66%.The investment community will be closely monitoring the performance of Gil ...

Gilead Sciences (GILD) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended March 2024. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 25. ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.Shares of this HIV and hepatitis C drugmaker have returned -7.5% over the past month versus the Zacks S&P 500 composite's -0.9% change. The Zacks Medical - Biomedical and Genetics industry, to which Gilead belongs, has lost 7.5% over this period. Now the key question is: Where could the stock be headed in the ...

Gilead Sciences (GILD) closed the most recent trading day at $69.94, moving +0.75% from the previous trading session. The stock outpaced the S&P 500's daily gain of 0.15%. On the other hand, the Dow registered a loss of 0.02%, and the technology-centric Nasdaq increased by 0.32%.Prior to today's trading, shares of the HIV and hepatitis C drugmaker had lost 7.83% over the past month. This has lagged the Medical sector's loss of 4.03% and the S&P 500's gain of 1.65% in that time.Investors will be eagerly watc ...

With strong market performance in recent periods, finding stocks priced at a discount can be challenging. However, examining stocks at 52-week lows may identify equities valued below their potential. While exercising caution is prudent, given valid underperformance reasons exist, comparing current metrics to historical peaks could reveal bargain stocks at 52-week lows. Understanding the drivers of underperformance provides insight into rebound likelihood.Since recovery duration may mirror price declines giv ...

Gilead Sciences (GILD) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Shares of this HIV and hepatitis C drugmaker have returned -1.2% over the past month versus the Zacks S&P 500 composite's +1.5% change. The Zacks Medical - Biomedical and Genetics industry, to which Gilead belongs, has lost 3.2% over this period. Now the key question is: Where could the stock be ...